{"version":1,"type":"rich","provider_name":"Libsyn","provider_url":"https:\/\/www.libsyn.com","height":90,"width":600,"title":"Reimagining Gene and Cell Therapy: Helen Sabzevari on Precigen\u2019s Breakthroughs in Precision Medicine","description":"In this episode of BioTalk, Rich Bendis welcomes Dr. Helen Sabzevari, President and CEO of Precigen, to discuss the company\u2019s cutting-edge science in gene and cell therapy. Dr. Sabzevari shares how Precigen\u2019s unique AdenoVerse\u00ae platform has powered the development of PRGN-2012, a potential first-in-class therapeutic currently under FDA priority review for the treatment of adults with recurrent respiratory papillomatosis (RRP), a rare and devastating disease. She also highlights advances across Precigen\u2019s broader pipeline in immuno-oncology and autoimmune disease and reflects on how Maryland\u2019s BioHealth Capital Region has supported the company\u2019s innovation and growth.   Editing and post-production work for this episode was provided by The Podcast Consultant.   Dr. Helen Sabzevari is the President and CEO of Precigen, Inc., and a leading expert in immunotherapy-based therapeutics. She previously served in executive roles at Compass Therapeutics and Merck KGaA\/EMD Serono, where she advanced numerous immuno-oncology programs. Dr. Sabzevari began her career at the National Cancer Institute and has been widely recognized for her leadership and scientific contributions, including honors from NIH, SITC, and Forbes. ","author_name":"BioTalk with Rich Bendis","author_url":"http:\/\/www.biohealthinnovation.org\/","html":"